Komori
Governance4563AnGes,Inc.Pharmaceuticals

Report on Corporate Governance 2026/07/16

As a company with an Audit & Supervisory Board, the Board of Directors comprises 4 directors, including 2 outside directors, and the Audit & Supervisory Board comprises 3 Audit & Supervisory Board Members, all of whom are outside members. The report does not state any changes from the previous report.

Worth reading
48Recurring
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit & Supervisory Board
Board of Directors4 membersof which 2 outside50.0%
Half
OutsideIn-house

社外取締役は、その会社の出身ではない取締役です。半数の線を超えると、取締役会の多数を社外の人が占めることになります。The percentage represented by the dotted line was calculated from the publicly disclosed number of people.

Committee1
Risk and Compliance Committee (percentage of outside committee members: not disclosed)
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit & Supervisory Board
Number of directorsTotal number 4 / Of which, outside 2
CommitteeRisk and Compliance Committee (percentage of outside committee members: not disclosed)
Items this document does not state (5)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The report does not explain the reasons for this board structure or composition of officers.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Report on Corporate Governance 2026/07/16 | AnGes,Inc. (4563) timely disclosure | Komori